WO1999048505A1 - Pharmacological composition based on minerals - Google Patents

Pharmacological composition based on minerals Download PDF

Info

Publication number
WO1999048505A1
WO1999048505A1 PCT/ES1998/000076 ES9800076W WO9948505A1 WO 1999048505 A1 WO1999048505 A1 WO 1999048505A1 ES 9800076 W ES9800076 W ES 9800076W WO 9948505 A1 WO9948505 A1 WO 9948505A1
Authority
WO
WIPO (PCT)
Prior art keywords
ppm
minerals
dermatological
cosmetic
composition
Prior art date
Application number
PCT/ES1998/000076
Other languages
Spanish (es)
French (fr)
Inventor
Pedro Fernandez De Haro
Original Assignee
Pedro Fernandez De Haro
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pedro Fernandez De Haro filed Critical Pedro Fernandez De Haro
Priority to PCT/ES1998/000076 priority Critical patent/WO1999048505A1/en
Publication of WO1999048505A1 publication Critical patent/WO1999048505A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/44—Elemental carbon, e.g. charcoal, carbon black
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/02—Medicinal preparations containing materials or reaction products thereof with undetermined constitution from inanimate materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/25—Silicon; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/26—Aluminium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/27—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
    • A61K8/29—Titanium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof

Definitions

  • the technical sector to which the invention relates is the chemical, pharmacological and cosmetic. It is a therapeutic and pharmacological composition formed by a combination of minerals that acts as a therapeutic, cosmetic and sanitary agent, for the treatment of pathologies such as carcinomas, HIV and other immunological problems, also verifying important cosmetic and dermatological healing effects.
  • carcinomas and HIV are carried out through methods, to a greater or lesser extent, physically painful, with an unattractive presentation for the patient.
  • This invention also brings a novelty for its simplicity to carry it out and its absence of harmfulness to the patient.
  • a mixture of the following components is carried out, in the proportions that are set: GOLD, (0.02 PPM), SILICA, (30.40%), ALUMINA, (13.03%), TITANIUM (0.98%), CALCIUM, (28.08%), MAGNESIUM (6.4%), POTASSIC (1.06%), MANGANESE (1.07%), IRON, (3.4%), SILVER (15 PPM), ZINC, (155 PPM), COPPER (0.061%), COBALT (0.013%), NICKEL (0.016%) AND CARBONIC (9.45%) allowing to rest and then micronizing to obtain a greater fineness of dust Low density gray, in which the preparation is in a form suitable for oral administration by means of capsules.
  • the powder obtained through the described procedure an adequate amount of gelatin will be incorporated so that it takes the form of a cream and can be properly administered on the skin covering the affected area until completely absorbed.
  • the production must be carried out from the lands that have the combination of specified minerals and their industrial development, once the product is approved, it does not offer more difficulty than any cosmetic or pharmacological product.

Abstract

The invention applies to the chemical, pharmacological and cosmetic fields with the object to combine totally natural products having immunological, oncological, dermatological and cosmetic properties. The formula or description of the invention results from the mixture of the following components in determined proportions: gold (0.02 ppm), silica (30.40 %), alumina (13.03 %), titanium (0.98 %), calcium (28.08 %), magnesium (6.4 %), potassium (1.06 %), manganese (1.07 %), iron (3.4 %), silver (15 ppm), zinc (155 ppm), copper (0.061 %), cobalt (0.016 %), nickel (0.016 %) and carbon (9.45 %).

Description

1 DESCRIPCIÓN 1 DESCRIPTION
COMPOSICIÓN FARMACOLÓGICA A BASE DE MINERALESMINERAL BASED PHARMACOLOGICAL COMPOSITION
El sector técnico al que se refiere la invención es el químico, farmacológico y cosmético. Es una composición terapéutica y farmacológica formada por una combinación de minerales que actúa como agente terapéutico, cosmético y sanitario, para el tratamiento de patologías como carcinomas, VIH y demás problemas inmunológicos, verificándose también importantes efectos cosméticos y curativos dermatológicos.The technical sector to which the invention relates is the chemical, pharmacological and cosmetic. It is a therapeutic and pharmacological composition formed by a combination of minerals that acts as a therapeutic, cosmetic and sanitary agent, for the treatment of pathologies such as carcinomas, HIV and other immunological problems, also verifying important cosmetic and dermatological healing effects.
La técnica anterior, en cuanto a las aplicaciones como producto terapéutico nos permite constatar que el ser humano ha utilizado durante cientos de años, compuestos minerales como una fuente de medicamentos para el tratamiento de cualquier afección. La aptitud de una amplia variedad de minerales ha sido investigada en cuanto a su potencial terapéutico . No obstante, ninguna técnica anterior, ni de las registradas, enseña ni sugiere una combinación específica compuesta por la combinación exacta y en las proporciones fijadas y sólo por los minerales que a continuación describimos: ORO, (0,02 P.P.M.), SÍLICE, (30,40%), ALUMINA, (13,03%), TITANIO (0,98%), CALCIO, (28,08%), MAGNESIO (6,4%), POTÁSICO (1,06%), MANGANESO (1,07%), HIERRO, (3,4%), PLATA (15 P.P.M.), ZINC, (155 P.P.M.), COBRE (0,061%), COBALTO (0,013%), NÍQUEL (0,016%) Y CARBÓNICO (9,45%). Tampoco la técnica anterior sugiere la utilidad de dicha combinación como agente farmacéutico útil para el tratamiento de patologías como carcinomas, VIH, problemas inmunológicos y patologías dermatológicas. El VIH está tratado últimamente con una combinación de retrovirales e inhibidores de la proteasa y, hasta hace poco, sólo se trataba con retrovirales, logrando un aumento de los T4 y una reducción de la carga viral. Pero, cualquiera de las dos terapias, son fuertemente agresivas para el paciente dañando órganos vitales como el hígado, estómago, ríñones y bazo. Por el contrario, esta invención, que consiste en un producto natural, es absolutamente inocua para el paciente sin efectos secundarios ninguno demostrados. Los carcinomas en la actualidad son tratados con agentes quimioterapeúticos que ocasionan daños físicos al paciente a la vez que se disminuyen sus defensas, siendo, por lo tanto, tratamientos agresivos. 2 No existiendo así tratamientos que consisten en productos naturales no nocivos para el paciente que, a la vez, combatan la formación de las células cancerosas bajando los marcadores tumorales. Por otro lado, para las patologías dermatológicas, aunque existen una gran variedad de productos naturales, algunos de dudosa efectividad, no se reconoce ninguno en este compuesto que está formado únicamente por minerales y, en concreto, por la exacta combinación de los mismos ya especificada.The prior art, as regards the applications as a therapeutic product, allows us to verify that the human being has used mineral compounds for hundreds of years as a source of medicines for the treatment of any condition. The ability of a wide variety of minerals has been investigated for their therapeutic potential. However, no prior technique, neither of those registered, teaches or suggests a specific combination composed of the exact combination and in the fixed proportions and only by the minerals described below: GOLD, (0.02 PPM), SILICA, ( 30.40%), ALUMINUM, (13.03%), TITANIUM (0.98%), CALCIUM, (28.08%), MAGNESIUM (6.4%), POTASSIC (1.06%), MANGANESE ( 1.07%), IRON, (3.4%), SILVER (15 PPM), ZINC, (155 PPM), COPPER (0.061%), COBALT (0.013%), NICKEL (0.016%) AND CARBONIC (9, Four. Five%). Nor does the prior art suggest the usefulness of said combination as a pharmaceutical agent useful for the treatment of pathologies such as carcinomas, HIV, immunological problems and dermatological pathologies. HIV has been treated lately with a combination of retrovirals and protease inhibitors and, until recently, it was only treated with retrovirals, achieving an increase in T4 and a reduction in viral load. But, either of the two therapies, are strongly aggressive for the patient damaging vital organs such as liver, stomach, kidneys and spleen. On the contrary, this invention, which consists of a natural product, is absolutely harmless to the patient without any proven side effects. Carcinomas are currently treated with chemotherapeutic agents that cause physical damage to the patient while reducing their defenses, being, therefore, aggressive treatments. 2 Thus, there are no treatments that consist of natural products that are not harmful to the patient that, at the same time, fight the formation of cancer cells by lowering the tumor markers. On the other hand, for dermatological pathologies, although there are a wide variety of natural products, some of doubtful effectiveness, none is recognized in this compound that is formed solely by minerals and, in particular, by the exact combination of them already specified .
Además, el tratamiento actual de carcinomas y VIH se realiza a través de métodos, en mayor o menor medida, físicamente dolorosos, con una presentación poco atractiva para el paciente.In addition, the current treatment of carcinomas and HIV is carried out through methods, to a greater or lesser extent, physically painful, with an unattractive presentation for the patient.
Esta invención también aporta una novedad por su sencillez para llevarla a cabo y su ausencia de nocividad para el paciente.This invention also brings a novelty for its simplicity to carry it out and its absence of harmfulness to the patient.
Tampoco es nada despreciable el bajo costo del producto. Para llevar a cabo la invención de la combinación de minerales, basta su adecuado tratamiento y en las proporciones adecuadas.Nor is the low cost of the product negligible. To carry out the invention of the combination of minerals, its adequate treatment and in the appropriate proportions is sufficient.
El procedimiento es el siguiente:The procedure is the next:
En un molino mezclador, se procede a realizar una mezcla de los siguientes componentes, en las proporciones que se fijan: ORO, (0,02 P.P.M.), SÍLICE, (30,40%), ALUMINA, (13,03%), TITANIO (0,98%), CALCIO, (28,08%), MAGNESIO (6,4%), POTÁSICO (1,06%), MANGANESO (1,07%), HIERRO, (3,4%), PLATA (15 P.P.M.), ZINC, (155 P.P.M.), COBRE (0,061%), COBALTO (0,013%), NÍQUEL (0,016%) Y CARBÓNICO (9,45%) dejando reposar y micronizando seguidamente para obtener una mayor finura de polvo gris de baja densidad, en la que el preparado se encuentra en una forma apropiada para su administrado oralmente mediante cápsulas.In a mixing mill, a mixture of the following components is carried out, in the proportions that are set: GOLD, (0.02 PPM), SILICA, (30.40%), ALUMINA, (13.03%), TITANIUM (0.98%), CALCIUM, (28.08%), MAGNESIUM (6.4%), POTASSIC (1.06%), MANGANESE (1.07%), IRON, (3.4%), SILVER (15 PPM), ZINC, (155 PPM), COPPER (0.061%), COBALT (0.013%), NICKEL (0.016%) AND CARBONIC (9.45%) allowing to rest and then micronizing to obtain a greater fineness of dust Low density gray, in which the preparation is in a form suitable for oral administration by means of capsules.
Para tratamiento de afecciones cutáneas, al polvo obtenido a través del procedimiento descrito, se le incorporará una cantidad adecuada de gelatina para que adopte la forma de una crema y pueda ser administrado correctamente sobre la piel cubriéndose la zona afectada hasta su completa absorción. La producción debe realizarse a partir de los terrenos que poseen la combinación de minerales especificados y su desarrollo industrial, una vez homologado el producto, no ofrece más dificultad que cualquier producto cosmético o farmacológico. For the treatment of skin conditions, the powder obtained through the described procedure, an adequate amount of gelatin will be incorporated so that it takes the form of a cream and can be properly administered on the skin covering the affected area until completely absorbed. The production must be carried out from the lands that have the combination of specified minerals and their industrial development, once the product is approved, it does not offer more difficulty than any cosmetic or pharmacological product.

Claims

3 REIVINDICACIONES 3 CLAIMS
1.- Composición farmacéutica caracterizada por consistir en la combinación exacta de los siguientes minerales en las proporciones fijadas: ORO, (0,02 P.P.M.), SÍLICE, (30,40%), ALUMINA, (13,03%), TITANIO (0,98%), CALCIO, (28,08%), MAGNESIO (6,4%), POTÁSICO (1,06%), MANGANESO (1,07%), HIERRO, (3,4%), PLATA (15 P.P.M.), ZINC, (155 P.P.M.), COBRE (0,061%), COBALTO (0,013%), NÍQUEL (0,016%) Y CARBÓNICO (9,45%) sin aditivo químico alguno siendo un producto totalmente natural.1.- Pharmaceutical composition characterized by consisting of the exact combination of the following minerals in the fixed proportions: GOLD, (0.02 PPM), SILICA, (30.40%), ALUMINA, (13.03%), TITANIUM ( 0.98%), CALCIUM, (28.08%), MAGNESIUM (6.4%), POTASSIC (1.06%), MANGANESE (1.07%), IRON, (3.4%), SILVER ( 15 PPM), ZINC, (155 PPM), COPPER (0.061%), COBALT (0.013%), NICKEL (0.016%) AND CARBONIC (9.45%) without any chemical additive being a totally natural product.
2.- Utilización de la composición expresada en la reivindicación 1, para la fabricación de un medicamento como agente terapéutico, cosmético y sanitario, carazterizado por su o aplicación en el tratamiento de carcinomas, combatiendo la formación de células cancerosas y reduciendo los tumores, del VIH logrando la reducción de la carga viral y aumento de las defensas (T4) y de las células T auxiliadores de linfocitos, llegando a negativizar la enfermedad y de las patologías dermatológicas.2. Use of the composition expressed in claim 1, for the manufacture of a medicament as a therapeutic, cosmetic and sanitary agent, characterized by its or application in the treatment of carcinomas, combating the formation of cancer cells and reducing tumors, of HIV achieving the reduction of the viral load and increase of the defenses (T4) and of the helper cells of lymphocytes, getting to negativize the disease and of the dermatological pathologies.
3 - Procedimiento de preparación de la composición expresada en la reivindicación 1, 5 caracterizada por ser combinados los minerales naturales a través de un molino mezclador en las proporciones fijadas, dejando reposar y micronizando seguidamente la mezcla para obtener una mayor finura de polvo en la que el preparado se encuentra en una forma apropiada para ser administrado oralmente mediante cápsulas. 4.- Composición que según la reivindicación 3, caracterizado porque puede añadírsele o una cantidad adecuada de gelatina, para que adopte la forma de una crema, para una correcta aplicación en los procedimientos dermatológicos. 3 - Method of preparing the composition expressed in claim 1, characterized in that the natural minerals are combined through a mixing mill in the fixed proportions, then allowing the mixture to stand and then micronizing to obtain a greater fineness of powder in which The preparation is in an appropriate form to be administered orally by capsules. 4. Composition according to claim 3, characterized in that it can be added or a suitable amount of gelatin, so that it takes the form of a cream, for a correct application in dermatological procedures.
PCT/ES1998/000076 1998-03-26 1998-03-26 Pharmacological composition based on minerals WO1999048505A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/ES1998/000076 WO1999048505A1 (en) 1998-03-26 1998-03-26 Pharmacological composition based on minerals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/ES1998/000076 WO1999048505A1 (en) 1998-03-26 1998-03-26 Pharmacological composition based on minerals

Publications (1)

Publication Number Publication Date
WO1999048505A1 true WO1999048505A1 (en) 1999-09-30

Family

ID=8302424

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES1998/000076 WO1999048505A1 (en) 1998-03-26 1998-03-26 Pharmacological composition based on minerals

Country Status (1)

Country Link
WO (1) WO1999048505A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890857A1 (en) * 2005-09-22 2007-03-23 Bulgari Parfums Sa COMPOSITION BASED ON MINERAL CONCENTRATES DERIVED FROM PRECIOUS STONES.

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0401445A1 (en) * 1989-05-31 1990-12-12 Alix-Roland Commin Aqueous preparation based on inorganic salts and acetic acid for the prevention and treatment of viral diseases
US5069912A (en) * 1985-02-19 1991-12-03 Jensen Charles A Method of treating spastic colitis
CH684630A5 (en) * 1992-08-21 1994-11-15 Danielle Girardet Pharmaceutical composition based on trace elements
EP0631785A1 (en) * 1993-07-01 1995-01-04 Hatutio Co., Ltd Mineral ion solution, anti-human immunodeficiency virus agent, and aids-treating agent

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5069912A (en) * 1985-02-19 1991-12-03 Jensen Charles A Method of treating spastic colitis
EP0401445A1 (en) * 1989-05-31 1990-12-12 Alix-Roland Commin Aqueous preparation based on inorganic salts and acetic acid for the prevention and treatment of viral diseases
CH684630A5 (en) * 1992-08-21 1994-11-15 Danielle Girardet Pharmaceutical composition based on trace elements
EP0631785A1 (en) * 1993-07-01 1995-01-04 Hatutio Co., Ltd Mineral ion solution, anti-human immunodeficiency virus agent, and aids-treating agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 1994-349923 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2890857A1 (en) * 2005-09-22 2007-03-23 Bulgari Parfums Sa COMPOSITION BASED ON MINERAL CONCENTRATES DERIVED FROM PRECIOUS STONES.
WO2007034088A2 (en) * 2005-09-22 2007-03-29 Bulgari Parfums Sa Composition based on mineral concentrates derived for precious stones
WO2007034088A3 (en) * 2005-09-22 2007-06-14 Bulgari Parfums Sa Composition based on mineral concentrates derived for precious stones

Similar Documents

Publication Publication Date Title
ES2292643T3 (en) TREATMENT OF THE COLLATERAL EFFECTS OF STATIN.
ES2439741T3 (en) Composition comprising components of crustacean gastrolites, calcium carbonate and their use
RU2007145489A (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CANCER AND ITS METASTASES
CN102357100A (en) Anti-tumor combination medicament
Chen et al. Apoptotic effect of cisplatin and cordycepin on OC3 human oral cancer cells
IL158668A0 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
US20110033376A1 (en) Treatment of Melanoma
WO2018039755A1 (en) Zinc- and quercetin-based pharmaceutical formulation for the production of antiviral medication effective for dengue and zika
ES2733938T3 (en) Biologically active food additive to normalize thyroid gland function
US20060240119A1 (en) Pharmacologically active strong acid solutions
BR9915729A (en) Egamega amides of n-arylsulfonyl-amino acid
OA12862A (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone.
PE20031047A1 (en) TREATMENT OF POST-MENOPAUSAL PATIENTS IN PATIENTS WITH BREAST CANCER
Liau et al. Winning formulas to fulfill cancer moonshot
WO1999048505A1 (en) Pharmacological composition based on minerals
MXPA03009483A (en) Toluene sulfonamide-containing anti-tumor composition and method of use thereof.
ES2277620T3 (en) CALCIUM TRIFLUOROACETATE WITH CYTOTOXIC ACTIVITY.
RU2345086C2 (en) Method of obtaining cis-diammonium-dichlorodihydroxoplatinum (iv) and its application
ES2215307T3 (en) COMPOSITIONS WITH SYNERGIC ACTION TO SELECTIVELY COMBAT TUMOR FABRICS.
MY119575A (en) Sulfonamide-substituted chromans, processes for their preparation, their use as a medicament or diagnostic, and pharmaceutical preparations comprising them
DE3823735A1 (en) Use of D-leucine (dextrorotatory alpha -amino isocaproic acid) as active substance for controlling malignant tumours of the mucosal epithelium of the entire intestinal tract including the pancreas and gall bladder
ATE91890T1 (en) MANUFACTURE OF A DRUG AGAINST ARTHRITIS AND RHEUMATISM.
BR0009327A (en) Pharmaceutical composition for therapy of lower urinary tract symptoms
ES2318541T3 (en) USEFUL THERAPEUTIC AGENT FOR THE TREATMENT OF PLASMATIC CELL NEOPLASIAS.
EL-Hak et al. Influence of injection mode and antioxidant dietary on the toxicity of Doxorubicin as a chemotherapy drug

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase